-+ 0.00%
-+ 0.00%
-+ 0.00%

*Ironwood Pharmaceuticals Sees FY26 LINZESS U.S. Net Sales of $1.125B to $1.175B Driven by Improved Net Price and Low-Single Digit Percentage Demand Growth >IRWD

Dow Jones·01/02/2026 12:10:00

Please log in to view news